Found 548 clinical trials
Insight Into the UAE Experience With Monoclonal Antibodies (Sotrovimab ) (EHS-Strategy)
Sotrovimab is a newly developed monoclonal antibody for the treatment of mild and moderate COVID-19 patient, who are at high risk for progression to severe COVID-19, including hospitalization or death. This includes, for example, individuals who are 65 years of age and older or individuals who have certain medical conditions. …
- 0 views
- 07 Dec, 2021
- 1 location
Novel Face Mask Sampling for COVID-19: A Diagnostic and Public Health Tool
The investigators have previously demonstrated the utility of this method in other respiratory infections, such as tuberculosis. This project aims to investigate the utility of mask-based sampling is a tool for the diagnosis and quantification of COVID-19 in breath and the implications in a healthcare setting using three cohorts of …
- 0 views
- 05 Aug, 2020
Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients
The recent COVID-19 outbreak has put the health care workers on the frontline to interact and provide support to the patients. Based on previous disease outbreak-associated studies, it is evident that these individuals are at a high-risk of developing psychological distress such as burnout, anxiety, depression, and stress (BADS). Thus, …
- 0 views
- 16 Feb, 2024
- 1 location
Rehabilitation Needs After COVID-19 Hospital Treatment
SARS-CoV-2 is a highly contagious new virus, causing an influenza like illness and respiratory tract infection demonstrating fever (89%), cough (68%), fatigue (38%), sputum production (34%) and/or shortness of breath (19%). The aim of this observational study is to detect symptoms, disabilities, participation and the lived experience of the disease …
- 0 views
- 05 Aug, 2020
Cardiovascular Consequences After COVID-19
The occurrence of cardiovascular complications in SARS-CoV-2 infections appears to be more frequent than in other viral respiratory infections, probably due to a singular pathophysiology of this coronavirus. The lack of characterization of cardiovascular damages linked to Covid-19 could have medium and long-term consequences on the prognosis of patients.
- 0 views
- 16 Feb, 2024
- 1 location
Construct Validation of the BIOTICA Questionnaire
Based on barriers identified in a systematic literature search, a self-report questionnaire called "BIOTICA" has been developed by the research team to assess medication adherence barriers to oral AB. The purpose of the BIOTICA-questionnaire is to detect individual barriers that prevent the optimal intake of oral AB and thus, lead …
- 0 views
- 16 Feb, 2024
- 1 location
COVID 19 Preventive Measures Among Mansoura Nursing Students
This study aims to identify nursing students knowledge gaps, risk perceptions and adherence to COVID 19 preventive measures during written exam period and In addition due to the possibility of being infected with COVID-19 during exams this study will evaluate covid-19 symptoms rate during exam period and factors affecting its …
- 0 views
- 05 Aug, 2020
Quality of Life and Physical Performance After Novel Coronavirus Infection (COVID-19);
This study aims to observe the long-term health-related quality of life (HRQOL) and physical performance in individuals hospitalized due to a COVID-19 infection. Therefore, data is extracted from a study-site standard aftercare program which has been adjusted for this patient population. This comprehensive aftercare program includes education sessions and physical …
- 0 views
- 05 Aug, 2020
Application of Serial Body Composition Change for Risk Prediction in Treating Patients With Severe Pneumonia
We hypothesize that serial changes of body composition in patients with pneumonia can help clinician to monitor prognosis. It was associated with underlying immune response.
- 0 views
- 16 Feb, 2024
- 1 location
Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children
This study will evaluate the persistence of immunogenicity following a reduced dosing schedule of 10- or 13-valent Pneumococcal Conjugate Vaccine (PCV10, PCV13). This is the follow-up of a randomized controlled trial in which children received a single priming dose of PCV10 or PCV13 (at 6 or 14 weeks of age) …
- 0 views
- 16 Feb, 2024
- 1 location